Vorinostat in vivo pharmacokinetics and pharmacodynamics

Pharmacokinetic (PK) and PD data for in vivo modeling were extracted from literature and digitized using GraphClick software (http://www.arizona-software.ch/graphclick/). The PK data consisted of a 10 mg/kg single i.v. bolus administered to female BALB/c nude mice,23 and PD data consisted of CB‐17 SCID mice bearing patient derived LAGκ‐1β multiple myeloma tumors treated with a 35 day vorinostat dosing regimen of 30, 60, or 100 mg/kg for 5 consecutive days every week, and 100 or 300 mg/kg once daily on 2 consecutive days every week.24 The 30 mg/kg dosing group was not included in this analysis as the tumor volume for these animals was greater than the vehicle control animals.